Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TYLENOL vs ARTESUNATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.
Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.
Mild to moderate pain (FDA-approved),Fever (FDA-approved),Osteoarthritis pain (off-label),Patent ductus arteriosus in neonates (off-label IV formulation)
Severe malaria (parenteral therapy),Uncomplicated malaria (combination therapy with other antimalarials),Off-label: Treatment of chloroquine-resistant falciparum malaria
650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.
2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.
Terminal elimination half-life is 2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment
Terminal elimination half-life of artesunate is approximately 1 hour. The active metabolite dihydroartemisinin has a half-life of 1-2 hours. This short half-life supports rapid parasite clearance in severe malaria.
Primarily hepatic via conjugation with glucuronide (UGT1A1, UGT1A6, UGT1A9) and sulfate (SULT1A1, SULT1A3); minor oxidation by CYP2E1, CYP1A2, and CYP3A4 to N-acetyl-p-benzoquinone imine (NAPQI), which is detoxified by glutathione.
Primarily hydrolyzed in the stomach and in plasma by esterases to dihydroartemisinin (DHA), the active metabolite. DHA undergoes glucuronidation via UGT1A9 and UGT2B7.
Renal excretion of conjugated metabolites (glucuronide and sulfate conjugates) accounts for >90% of elimination; less than 5% excreted unchanged; minor biliary/fecal elimination (<5%)
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% as unchanged drug. Biliary/fecal elimination is minimal. ~80% of the dose is recovered in urine as metabolites, mainly dihydroartemisinin.
10-25% bound to plasma proteins (primarily albumin); binding is minimal and not clinically significant
Artemisinin derivatives: ~93% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein.
0.8-1.0 L/kg; low Vd indicates limited extravascular distribution, consistent with limited CNS penetration
Vd approximately 0.6-0.8 L/kg, indicating distribution into total body water. Higher Vd in severe malaria due to increased capillary permeability.
Oral: 60-90% (first-pass hepatic metabolism reduces bioavailability); Rectal: 70-90%; Intravenous: 100%
Oral: ~40% (range 20-50%) due to first-pass metabolism. Rectal: ~40-60%. IV: 100%.
GFR 10-50 m L/min: Administer every 6 hours. GFR <10 m L/min: Administer every 8 hours.
No dose adjustment required for any degree of renal impairment.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50%; maximum 2000 mg/day. Child-Pugh C: Reduce dose by 75%; maximum 1000 mg/day.
No dose adjustment required for Child-Pugh A or B; caution in Child-Pugh C due to limited data.
10-15 mg/kg orally every 4-6 hours; maximum 75 mg/kg/day or 5 doses per day.
2.4 mg/kg IV at 0, 12, 24, and 48 hours; weight-based (minimum 2.4 mg/kg per dose).
Reduce dose by 25-50% in frail elderly; maximum 3000 mg/day due to increased hepatotoxicity risk.
No specific dose adjustment; use same dosing as adults with monitoring for adverse effects.
Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen in doses exceeding 4000 mg per day. The risk of acute liver failure may be higher in individuals with underlying liver disease and in those who consume alcohol chronically.
None.
Hepatotoxicity: Risk increases with doses > 4000 mg/day, chronic alcohol use, or preexisting liver disease.,Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis.,Hypersensitivity: Rare anaphylaxis.
Hemolysis: Cases of delayed hemolytic anemia have been reported, especially in patients with high parasitemia.,Cardiotoxicity: Theoretical risk of QT prolongation with co-administration of other QT-prolonging drugs.,Hypersensitivity: Severe allergic reactions (e.g., anaphylaxis) have occurred.
Hypersensitivity to acetaminophen,Severe hepatic impairment (e.g., active liver disease)
Hypersensitivity to artesunate, any artemisinin derivative, or any component of the formulation.,Pregnancy: Not recommended in first trimester unless life-threatening; avoid in second/third trimester if safer alternatives available.,Breastfeeding: Safety not established; discontinue breast-feeding or avoid drug.
No significant food interactions. Alcohol consumption increases risk of hepatotoxicity; avoid concurrent use. High-carbohydrate meals may slightly delay absorption.
No known significant food interactions. However, avoid grapefruit and grapefruit juice as they may alter drug metabolism (CYP2A6 inhibition). Maintain adequate hydration and nutrition to support recovery.
Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastroschisis and neural tube defects but confounding by indication is likely. Second and third trimesters: no consistent evidence of adverse fetal effects; chronic high doses may cause maternal hepatotoxicity with secondary fetal effects. Avoid prolonged high-dose therapy.
Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benefit of treating life-threatening malaria generally outweighs risks, as untreated malaria poses significant fetal risks. However, the drug should be used with caution and only when clearly needed.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio approximately 0.9; peak milk concentration 10-15 µg/m L after 1g oral dose). Relative infant dose is <2% of maternal weight-adjusted dose. Considered compatible with breastfeeding; monitor infant for rash or drowsiness.
Artesunate is excreted into breast milk in small amounts. The M/P ratio is not well-established. While the American Academy of Pediatrics considers artesunate compatible with breastfeeding, caution is advised, especially in nursing preterm or jaundiced infants. The benefits of breastfeeding and the necessity of maternal treatment should be weighed.
Increased clearance in pregnancy may reduce AUC by 25-30%; recommend standard dosing (500-1000mg every 4-6 hours, max 3000-4000mg/day). No dosage adjustment typically needed. Avoid extended-release formulations due to variable absorption.
No dose adjustment is required for artesunate during pregnancy based on pharmacokinetic changes. However, intravenous artesunate is the recommended treatment for severe malaria in the second and third trimesters. Oral artesunate may be used for uncomplicated malaria, but caution is advised in the first trimester due to teratogenicity.
Acetaminophen has minimal anti-inflammatory effect; prefer NSAIDs for inflammation. Max daily dose 3 g (or 2 g in at-risk patients). N-acetylcysteine is antidote for overdose; administer if serum level above nomogram line. Avoid in severe hepatic impairment. Intravenous formulation available for acute pain. Onset of action 30-60 min, duration 4-6 h. No effect on platelets or GI mucosa.
Artesunate is the first-line therapy for severe malaria (WHO recommendation). Administer IV or IM; IV dose is 2.4 mg/kg at 0, 12, and 24 hours then daily. Monitor for hypoglycemia and delayed hemolytic anemia (post-artesunate hemolysis). Not recommended for uncomplicated malaria due to risk of resistance. Artesunate is rapidly acting with a short half-life; always combine with a partner drug (e.g., artemether-lumefantrine) for complete cure. Do not use in first trimester of pregnancy unless life-threatening.
Do not exceed 3 g (3000 mg) per day from all products.,Check all over-the-counter medications for acetaminophen content.,Do not take with alcohol or if you have liver disease.,Seek immediate medical attention if overdose is suspected.,May be taken with food if GI upset occurs (though rare).
Take this medication exactly as prescribed; do not stop early even if you feel better.,You may experience temporary side effects such as dizziness, nausea, or fatigue; report any severe reactions.,This drug is used for severe malaria; you will likely be hospitalized for close monitoring.,Watch for signs of low blood sugar (sweating, confusion, rapid heartbeat) and report immediately.,Inform your healthcare provider about all medications you are taking, especially blood thinners or anti-seizure drugs.,Complete the full course of treatment, including any follow-up medications to prevent recurrence.
No interactions on record
"Nicotine, a known inducer of cytochrome P450 (CYP) enzymes, particularly CYP1A2 and possibly CYP2A6, may increase the hepatic metabolism of artesunate to its active metabolite dihydroartemisinin. This enhanced clearance can lead to subtherapeutic plasma concentrations of dihydroartemisinin, reducing the antimalarial efficacy of artesunate and potentially increasing the risk of treatment failure and the development of drug resistance."
"Amiodarone, a potent CYP3A4 and CYP2B6 inhibitor, can significantly reduce the systemic exposure of dihydroartemisinin, the active metabolite of artesunate. This occurs through inhibition of cytochrome P450 enzymes responsible for the conversion of artesunate to its active form, leading to decreased antimalarial efficacy. Clinically, this interaction may result in treatment failure or recrudescence of malaria when artesunate is co-administered with amiodarone."
"The coadministration of buprenorphine, a partial mu-opioid receptor agonist, with artesunate may reduce the systemic exposure of dihydroartemisinin (DHA), the primary active metabolite of artesunate, thereby decreasing antimalarial efficacy. This interaction is believed to occur through buprenorphine-mediated induction of cytochrome P450 (CYP) enzymes responsible for artesunate metabolism, leading to enhanced clearance and subtherapeutic concentration of DHA. Clinically, this could result in delayed parasite clearance and increased risk of treatment failure in malaria patients."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TYLENOL vs ARTESUNATE, answered by our medical review team.
TYLENOL is a Analgesic (non-opioid) that works by Acetaminophen is a centrally acting analgesic and antipyretic. Its mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system, preferentially COX-2, and modulation of descending serotonergic pathways.. ARTESUNATE is a Antimalarial that works by Artesunate is a water-soluble artemisinin derivative that produces rapid parasite clearance. It is converted in vivo to dihydroartemisinin, which generates free radicals that alkylate and damage parasite proteins, particularly targeting the sarcoplasmic/endoplasmic reticulum calcium ATPase (SERCA) of Plasmodium species.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TYLENOL and ARTESUNATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TYLENOL is: 650 mg orally every 4-6 hours or 1000 mg orally every 6 hours; maximum 4000 mg per day.. The standard adult dose of ARTESUNATE is: 2.4 mg/kg IV at 0, 12, 24, and 48 hours, then daily until oral therapy can be initiated.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TYLENOL and ARTESUNATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TYLENOL is classified as Category C. Acetaminophen crosses the placenta. First trimester: no increased risk of major malformations in prospective studies; retrospective studies show possible association with gastrosch. ARTESUNATE is classified as Category C. Artesunate is contraindicated in the first trimester of pregnancy due to embryotoxicity and teratogenicity observed in animal studies. In the second and third trimesters, the benef. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.